annb0t
Top 20
Pfizer PFE announced positive top-line data from the phase III BENEGENE-2 study, which evaluated fidanacogene elaparvovec, its investigational gene therapy, for the treatment of male adult patients with moderately severe to severe hemophilia B.
The BENGENE-2 study achieved its primary endpoint of non-inferiority and superiority in the annualized bleeding rate (ABR) of total bleeds post infusion with fidanacogene elaparvovec when compared to those study participants who were administered the cur...
>>> Read more: Pfizer's (PFE) Hemophilia B Gene Therapy Meets Study Goal
The BENGENE-2 study achieved its primary endpoint of non-inferiority and superiority in the annualized bleeding rate (ABR) of total bleeds post infusion with fidanacogene elaparvovec when compared to those study participants who were administered the cur...
>>> Read more: Pfizer's (PFE) Hemophilia B Gene Therapy Meets Study Goal
